CD8A and melanoma: TIGIT has proven to be of clinical interest due to its dual expression on tumor and immune cells, such as NKs and CD8+ tumor infiltrating T cells, and the positive correlation between TIGIT levels and PD-1 expression on human melanoma infiltrating CD8+ T cells [67,68].